明報新聞網

翰思艾泰伙晶泰研AI在抗體、創新分子設計及藥物研發流程等領域

21 9 月, 2026

One Min Read

3 Views

翰思艾泰（3378）公布，與深圳晶泰科技於近期正式簽署了戰略合作框架協議及XtalPi Science技術平台使用授權協議，探索AI for Science在抗體設計、創新分子設計及藥物研發流程優化等領域的應用。

原文: https://finance.mingpao.com/fin/instantf/20260921/1789989412879/%E7%BF%B0%E6%80%9D%E8%89%BE%E6%B3%B0%E4%BC%99%E6%99%B6%E6%B3%B0-%E7%A0%94ai%E5%9C%A8%E6%8A%97%E9%AB%94-%E5%89%B5%E6%96%B0%E5%88%86%E5%AD%90%E8%A8%AD%E8%A8%88%E5%8F%8A%E8%97%A5%E7%89%A9%E7%A0%94%E7%99%BC%E6%B5%81%E7%A8%8B%E7%AD%89%E9%A0%98%E5%9F%9F%22%20target=%22blank

Last Update: 21 9 月, 2026

Written By

Other Articles

Previous

<div>Bitcoin hits highest level since January at $85,000, as the market debates whether the ‘crypto winter’ is over</div>

Next

The corporate blockchain wars are heating up as Circle’s Arc goes live

Related Posts

明報新聞網

天氣｜天文台：大致多雲　日間部分時間有陽光

1 Min Read

明報新聞網

短片：西班牙葡萄牙恢復供電　停電期間火車、飛機停運

1 Min Read

明報新聞網

抽象派畫家Mark Rothko 4.4億元作品荷蘭展出　遭小孩刮花

1 Min Read

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept